| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Compensation Resources, Inc. Releases Its 2004 Turnover Survey |
|
Just Other Articles - Compensation Resources, Inc. Releases Its 2004 Turnover Survey
Upper Saddle River, N.J. - September 2004 - Compensation Resources, Inc. has released t According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product he results of its 2004 Turnover Survey. The purpose of this study was to obtain turnov ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in r statistics and trends. Data was compiled from survey questions that were developed b lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. CRI and distributed to companies in over ten industrial classifications, in addition t here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe Not-for-Profit organizations. The survey sampled turnover data from a variety of orga d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro izations, collected in July and August 2004. Results indicated that from May 31, 2003 ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc o May 31, 2004, the average voluntary turnover rate was 11.3%. The majority of respond easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi nts indicated this rate has either increased or remained the same, while only 20.9% of nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically articipants indicated this rate has decreased in the prior 12-month period. Of all emp and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ oyee functional groups, Administrative level and Production level positions show the hi ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi hest voluntary turnover rates; however, according to survey participants Administrative ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a and Production level positions also take the shortest amount of time to fill. Overall, dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod the cost of turnover to organizations is on average ? x the employee’s salary to 1x the cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin employee’s salary. Lastly, participants indicated that employees usually leave the org tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen nization because there is better pay and/or benefits offered elsewhere, better opportun t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ties/increased responsibilities offered somewhere else, or involuntarily due to company ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust layoff. Although some turnover is inevitable, organizations must take steps to control y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products turnover, particularly that caused by organizational factors such as poor supervision, . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de nadequate training, unfair pay systems, lack of communication, and inconsistent policie elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip . Human resource activities should be examined as part of the turnover control efforts tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Exploring The Different Types Of Corporate Parties Will Retail Chains Lose Their Dominance?
|